Published in Neurobiol Dis on July 01, 2002
Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect (2011) 3.87
Association of pesticide exposure with neurologic dysfunction and disease. Environ Health Perspect (2004) 2.79
Toxin-induced models of Parkinson's disease. NeuroRx (2005) 2.67
DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol (2004) 2.51
A targetable fluorescent probe for imaging hydrogen peroxide in the mitochondria of living cells. J Am Chem Soc (2008) 2.23
Mitochondria are a major source of paraquat-induced reactive oxygen species production in the brain. J Biol Chem (2007) 2.13
The perplexing paradox of paraquat: the case for host-based susceptibility and postulated neurodegenerative effects. J Biochem Mol Toxicol (2014) 2.03
Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism. PLoS Biol (2004) 2.02
Pesticides and Parkinson's disease--is there a link? Environ Health Perspect (2006) 2.01
Selective neuronal vulnerability to oxidative stress in the brain. Front Aging Neurosci (2010) 1.96
Lysosomal degradation of alpha-synuclein in vivo. J Biol Chem (2010) 1.82
Early environmental origins of neurodegenerative disease in later life. Environ Health Perspect (2005) 1.80
Parkinson's disease risk from ambient exposure to pesticides. Eur J Epidemiol (2011) 1.70
Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci (2009) 1.66
Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Exp Neurol (2010) 1.66
Boronate oxidation as a bioorthogonal reaction approach for studying the chemistry of hydrogen peroxide in living systems. Acc Chem Res (2011) 1.63
Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occup Environ Med (2007) 1.60
Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am J Pathol (2007) 1.52
Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin Neurosci Res (2006) 1.50
Animal models of Parkinson's disease progression. Acta Neuropathol (2008) 1.49
Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect (2003) 1.47
Classic and new animal models of Parkinson's disease. J Biomed Biotechnol (2012) 1.45
Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis (2006) 1.43
Quantification of Paraquat, MPTP, and MPP+ in brain tissue using microwave-assisted solvent extraction (MASE) and high-performance liquid chromatography-mass spectrometry. Anal Bioanal Chem (2009) 1.42
Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse (2007) 1.41
Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease. Free Radic Biol Med (2008) 1.38
A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harb Perspect Med (2011) 1.36
The Drosophila vesicular monoamine transporter reduces pesticide-induced loss of dopaminergic neurons. Neurobiol Dis (2010) 1.31
The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol Sci (2011) 1.31
The role of NADPH oxidase 1-derived reactive oxygen species in paraquat-mediated dopaminergic cell death. Antioxid Redox Signal (2009) 1.31
NF-κB in Aging and Disease. Aging Dis (2011) 1.28
Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. Int J Environ Res Public Health (2011) 1.27
Potential developmental neurotoxicity of pesticides used in Europe. Environ Health (2008) 1.25
Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system. Exp Neurol (2007) 1.24
Glutathione metabolism and Parkinson's disease. Free Radic Biol Med (2013) 1.20
Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog Neurobiol (2013) 1.20
Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J Immunol (2008) 1.18
Parkinson's disease: animal models and dopaminergic cell vulnerability. Front Neuroanat (2014) 1.18
The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis (2011) 1.15
Differential contribution of the mitochondrial respiratory chain complexes to reactive oxygen species production by redox cycling agents implicated in parkinsonism. Toxicol Sci (2009) 1.13
GSTpi expression mediates dopaminergic neuron sensitivity in experimental parkinsonism. Proc Natl Acad Sci U S A (2007) 1.11
Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. AAPS J (2006) 1.09
Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat. J Neurotrauma (2011) 1.08
Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci (2015) 1.07
Genetics of iron regulation and the possible role of iron in Parkinson's disease. Neurobiol Dis (2008) 1.07
Toxicokinetics and toxicodynamics of paraquat accumulation in mouse brain. Exp Neurol (2008) 1.06
Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener (2009) 1.05
Prolonged toxicokinetics and toxicodynamics of paraquat in mouse brain. Environ Health Perspect (2007) 1.04
Ziram causes dopaminergic cell damage by inhibiting E1 ligase of the proteasome. J Biol Chem (2008) 1.04
The role of early life environmental risk factors in Parkinson disease: what is the evidence? Environ Health Perspect (2005) 1.04
Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. Proc Natl Acad Sci U S A (2011) 1.03
Paraquat induces oxidative stress, neuronal loss in substantia nigra region and parkinsonism in adult rats: neuroprotection and amelioration of symptoms by water-soluble formulation of coenzyme Q10. BMC Neurosci (2009) 1.00
Animal models of the non-motor features of Parkinson's disease. Neurobiol Dis (2012) 1.00
Iron-enhanced paraquat-mediated dopaminergic cell death due to increased oxidative stress as a consequence of microglial activation. Free Radic Biol Med (2008) 0.99
Oxidative toxicity in neurodegenerative diseases: role of mitochondrial dysfunction and therapeutic strategies. J Toxicol (2011) 0.99
Trichloroethylene induces dopaminergic neurodegeneration in Fisher 344 rats. J Neurochem (2009) 0.99
Oxidative stress and cerebral endothelial cells: regulation of the blood-brain-barrier and antioxidant based interventions. Biochim Biophys Acta (2011) 0.98
Genomic and biochemical approaches in the discovery of mechanisms for selective neuronal vulnerability to oxidative stress. BMC Neurosci (2009) 0.98
Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience (2010) 0.97
Toxin models of mitochondrial dysfunction in Parkinson's disease. Antioxid Redox Signal (2011) 0.97
Paraquat, but not maneb, induces synucleinopathy and tauopathy in striata of mice through inhibition of proteasomal and autophagic pathways. PLoS One (2012) 0.97
Mitochondria and energetic depression in cell pathophysiology. Int J Mol Sci (2009) 0.95
Reactive oxygen species generation by the ethylene-bis-dithiocarbamate (EBDC) fungicide mancozeb and its contribution to neuronal toxicity in mesencephalic cells. Neurotoxicology (2007) 0.95
Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson's disease. Parkinsons Dis (2010) 0.95
Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models. Neurobiol Dis (2012) 0.94
Animal models of Parkinson's disease: a gateway to therapeutics? Neurotherapeutics (2014) 0.93
Quantitative determination of paraquat in meconium by sodium borohydride-nickel chloride chemical reduction and gas chromatography/mass spectrometry (GC/MS). J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.93
Single-cell redox imaging demonstrates a distinctive response of dopaminergic neurons to oxidative insults. Antioxid Redox Signal (2011) 0.92
Dopaminergic toxicity of the herbicide atrazine in rat striatal slices. Toxicology (2006) 0.92
Epigallocatechin gallate (EGCG) potentiates the cytotoxicity of rotenone in neuroblastoma SH-SY5Y cells. Brain Res (2007) 0.92
Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease. Front Neuroanat (2010) 0.92
Etiology of Parkinson's disease: Genetics and environment revisited. Proc Natl Acad Sci U S A (2002) 0.91
Evaluation of Models of Parkinson's Disease. Front Neurosci (2016) 0.90
Gene therapy in Parkinson's disease: rationale and current status. CNS Drugs (2010) 0.89
Mortality from Parkinson's disease and other causes among a workforce manufacturing paraquat: a retrospective cohort study. BMJ Open (2011) 0.89
Alteration of dopamine uptake into rat striatal vesicles and synaptosomes caused by an in vitro exposure to atrazine and some of its metabolites. Toxicology (2008) 0.88
Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration. J Neurochem (2010) 0.87
Impairment of striatal mitochondrial function by acute paraquat poisoning. J Bioenerg Biomembr (2015) 0.87
Coupling endoplasmic reticulum stress to the cell death program in dopaminergic cells: effect of paraquat. Neuromolecular Med (2008) 0.87
Paraquat toxicity induced by voltage-dependent anion channel 1 acts as an NADH-dependent oxidoreductase. J Biol Chem (2009) 0.87
Alterations in the striatal dopamine system during intravenous methamphetamine exposure: effects of contingent and noncontingent administration. Synapse (2013) 0.87
Neurodegenerative disorders: Parkinson's disease and Huntington's disease. J Neurol Neurosurg Psychiatry (2005) 0.87
Heat shock protein-70 (Hsp-70) suppresses paraquat-induced neurodegeneration by inhibiting JNK and caspase-3 activation in Drosophila model of Parkinson's disease. PLoS One (2014) 0.87
Differential Effects of Methyl-4-Phenylpyridinium Ion, Rotenone, and Paraquat on Differentiated SH-SY5Y Cells. J Toxicol (2013) 0.86
Pesticides, microglial NOX2, and Parkinson's disease. J Biochem Mol Toxicol (2013) 0.86
Molecular events underlying Parkinson's disease - an interwoven tapestry. Front Neurol (2013) 0.86
Association between Parkinson's Disease and Cigarette Smoking, Rural Living, Well-Water Consumption, Farming and Pesticide Use: Systematic Review and Meta-Analysis. PLoS One (2016) 0.85
Differential regional expression patterns of α-synuclein, TNF-α, and IL-1β; and variable status of dopaminergic neurotoxicity in mouse brain after Paraquat treatment. J Neuroinflammation (2011) 0.85
Nigrostriatal neuronal death following chronic dichlorvos exposure: crosstalk between mitochondrial impairments, α synuclein aggregation, oxidative damage and behavioral changes. Mol Brain (2010) 0.84
Emerging neurotoxic mechanisms in environmental factors-induced neurodegeneration. Neurotoxicology (2012) 0.83
Signaling pathways involved in 1-octen-3-ol-mediated neurotoxicity in Drosophila melanogaster: implication in Parkinson’s disease. Neurotox Res (2014) 0.83
Electrophilic adduction of ubiquitin activating enzyme E1 by N,N-diethyldithiocarbamate inhibits ubiquitin activation and is accompanied by striatal injury in the rat. Chem Res Toxicol (2012) 0.83
Rotenone and paraquat perturb dopamine metabolism: A computational analysis of pesticide toxicity. Toxicology (2013) 0.83
Natural toxins implicated in the development of Parkinson's disease. Ther Adv Neurol Disord (2011) 0.83
Assessing causal relationships in genomics: From Bradford-Hill criteria to complex gene-environment interactions and directed acyclic graphs. Emerg Themes Epidemiol (2011) 0.82
alpha-Synuclein: a therapeutic target for Parkinson's disease? Pharmacol Res (2008) 0.82
Targeting the progression of Parkinson's disease. Curr Neuropharmacol (2009) 0.82
Glutathione deficiency in Gclm null mice results in complex I inhibition and dopamine depletion following paraquat administration. Toxicol Sci (2013) 0.81
Molecular aspects of dopaminergic neurodegeneration: gene-environment interaction in parkin dysfunction. Int J Environ Res Public Health (2011) 0.81
Paraquat exposure reduces nicotinic receptor-evoked dopamine release in monkey striatum. J Pharmacol Exp Ther (2008) 0.80
Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl J Med (2003) 16.73
Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet (2011) 5.01
Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect (2011) 3.87
Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol (2004) 3.37
Solvent exposures and Parkinson disease risk in twins. Ann Neurol (2011) 2.92
Blood lead concentrations < 10 microg/dL and child intelligence at 6 years of age. Environ Health Perspect (2008) 2.81
Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci (2007) 2.28
Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol (2008) 2.04
The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem (2001) 1.99
Head injury and Parkinson's disease risk in twins. Ann Neurol (2006) 1.93
Lysosomal degradation of alpha-synuclein in vivo. J Biol Chem (2010) 1.82
Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci (2003) 1.80
Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur J Neurosci (2003) 1.77
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Maternal stress modulates the effects of developmental lead exposure. Environ Health Perspect (2004) 1.64
Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology (2009) 1.63
The outdoor air pollution and brain health workshop. Neurotoxicology (2012) 1.60
Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J Neurochem (2005) 1.59
Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol (2009) 1.56
Overexpression of superoxide dismutase or glutathione peroxidase protects against the paraquat + maneb-induced Parkinson disease phenotype. J Biol Chem (2005) 1.56
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol (2002) 1.54
Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol (2002) 1.51
Project TENDR: Targeting Environmental Neuro-Developmental Risks The TENDR Consensus Statement. Environ Health Perspect (2016) 1.50
Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis (2006) 1.43
Quantification of Paraquat, MPTP, and MPP+ in brain tissue using microwave-assisted solvent extraction (MASE) and high-performance liquid chromatography-mass spectrometry. Anal Bioanal Chem (2009) 1.42
Impaired neuropsychological functioning in lead-exposed children. Dev Neuropsychol (2004) 1.41
Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. Neurotoxicology (2002) 1.40
Mechanistic approaches to Parkinson's disease pathogenesis. Brain Pathol (2002) 1.39
MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS One (2008) 1.39
SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress. PLoS One (2011) 1.37
Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry (2003) 1.33
Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc Natl Acad Sci U S A (2002) 1.33
Retracted Sustained exposure to the widely used herbicide atrazine: altered function and loss of neurons in brain monoamine systems. Environ Health Perspect (2005) 1.30
Redox cycling of the herbicide paraquat in microglial cultures. Brain Res Mol Brain Res (2005) 1.27
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol (2007) 1.25
Interactions of chronic lead exposure and intermittent stress: consequences for brain catecholamine systems and associated behaviors and HPA axis function. Toxicol Sci (2005) 1.25
Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system. Exp Neurol (2007) 1.24
Heavy metal lead exposure, osteoporotic-like phenotype in an animal model, and depression of Wnt signaling. Environ Health Perspect (2012) 1.24
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol (2002) 1.22
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol (2007) 1.21
Aging of the nigrostriatal system in the squirrel monkey. J Comp Neurol (2004) 1.20
Lifetime consequences of combined maternal lead and stress. Basic Clin Pharmacol Toxicol (2008) 1.19
Crossroads in GDNF therapy for Parkinson's disease. Mov Disord (2006) 1.19
Environmental factors in Parkinson's disease. Neurotoxicology (2002) 1.18
The gestational environment and Parkinson's disease: evidence for neurodevelopmental origins of a neurodegenerative disorder. Reprod Toxicol (2007) 1.18
Fish consumption and prenatal methylmercury exposure: cognitive and behavioral outcomes in the main cohort at 17 years from the Seychelles child development study. Neurotoxicology (2011) 1.18
Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J Immunol (2008) 1.18
Interactive effects of a DRD4 polymorphism, lead, and sex on executive functions in children. Biol Psychiatry (2007) 1.18
Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol Aging (2006) 1.18
Developmental pesticide models of the Parkinson disease phenotype. Environ Health Perspect (2005) 1.17
Paraquat increases cyanide-insensitive respiration in murine lung epithelial cells by activating an NAD(P)H:paraquat oxidoreductase: identification of the enzyme as thioredoxin reductase. J Biol Chem (2007) 1.14
Head injury, α-synuclein Rep1, and Parkinson's disease. Ann Neurol (2012) 1.14
Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia. J Neurosci (2013) 1.14
Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J (2004) 1.13
Maternal PUFA status but not prenatal methylmercury exposure is associated with children's language functions at age five years in the Seychelles. J Nutr (2012) 1.12
Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J Biol Chem (2010) 1.11
Lead exposure inhibits fracture healing and is associated with increased chondrogenesis, delay in cartilage mineralization, and a decrease in osteoprogenitor frequency. Environ Health Perspect (2005) 1.11
Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter. Neurobiol Dis (2007) 1.11
Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus. Expert Rev Neurother (2009) 1.08
Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS One (2010) 1.08
Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J Neurochem (2006) 1.06
Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J Biol Chem (2006) 1.06
Gene-environment interactions in Parkinson's disease and other forms of parkinsonism. Neurotoxicology (2010) 1.06
Voluntarily simulated tremor in normal subjects. Neurophysiol Clin (2002) 1.03
Can cellular models revolutionize drug discovery in Parkinson's disease? Biochim Biophys Acta (2009) 1.03
Caudo-rostral brain spreading of α-synuclein through vagal connections. EMBO Mol Med (2013) 1.02
Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. J Neuropathol Exp Neurol (2008) 1.01
Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. J Neurosci (2006) 1.00
Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis (2005) 1.00
Paraquat neurotoxicity is mediated by a Bak-dependent mechanism. J Biol Chem (2007) 1.00
Effects of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration. J Neurochem (2003) 1.00
Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease. Toxicol Lett (2011) 0.99
Increases in alpha4* but not alpha3*/alpha6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment. J Neurochem (2006) 0.99
Decreased expression of the transcription factor NURR1 in dopamine neurons of cocaine abusers. Proc Natl Acad Sci U S A (2002) 0.99
Mitochondrial dysfunction in skin fibroblasts from a Parkinson's disease patient with an alpha-synuclein triplication. J Parkinsons Dis (2011) 0.98
Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variants. Parkinsonism Relat Disord (2012) 0.98
Increased synaptosomal dopamine content and brain concentration of paraquat produced by selective dithiocarbamates. J Neurochem (2003) 0.97
Early postnatal exposure to ultrafine particulate matter air pollution: persistent ventriculomegaly, neurochemical disruption, and glial activation preferentially in male mice. Environ Health Perspect (2014) 0.97
Implications of gender differences for human health risk assessment and toxicology. Environ Res (2006) 0.96
The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates. J Neurosci Methods (2005) 0.96
Small molecules greatly improve conversion of human-induced pluripotent stem cells to the neuronal lineage. Stem Cells Int (2012) 0.95
A fetal risk factor for Parkinson's disease. Dev Neurosci (2004) 0.95
Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol (2006) 0.95
Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2* nAChRs. J Neurochem (2007) 0.94
Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. J Neurochem (2013) 0.93
Stem cells for Parkinson disease and ALS: replacement or protection? Nat Med (2004) 0.93
Developmental exposure to concentrated ambient particles and preference for immediate reward in mice. Environ Health Perspect (2012) 0.92